Keytruda beats Yervoy and edges ahead of Opdivo in first-line melanoma
This article was originally published in Scrip
Executive Summary
Merck & Co pivotal Phase III KEYNOTE-006 study investigating the PD-1 inhibitor Keytruda (pembrolizumab) compared to Bristol-Myers Squibb's Yervoy (ipilimumab) in the first-line treatment of patients with advanced melanoma has met its two primary endpoints of progression-free survival (PFS) and overall survival (OS). The trial will be stopped early based on the recommendation of an independent data monitoring committee.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.